银杏叶提取物对4 种口服抗凝药抗凝活性的影响
刘志双， 郑玉粉， 孙红娜， 于锋 - 中国药科大学学报, 2020 - jcpu.cpu.edu.cn
… of 4 new oral anticoagulants (NOACs), dabigatran, apixaban, … ) and the activity of coagulation
factor Xa (FXa) of rat plasma … concentration of FXa inhibitors (apixaban, rivaroxaban and …
factor Xa (FXa) of rat plasma … concentration of FXa inhibitors (apixaban, rivaroxaban and …
Ⅹa 因子抑制剂治疗急性冠状动脉综合征的研究进展
赵梦华， 石建平， 张学强 - 临床急诊杂志, 2013 - whuhzzs.com
… novel procedural anticoagulants,such as selective factor-Xa inhibitors. The purpose of this
review is to summarize the evidence for factor Xa inhibitors in later phases of clinical testing. …
review is to summarize the evidence for factor Xa inhibitors in later phases of clinical testing. …
7 种新型口服抗凝药预防全髋, 膝关节置换术后静脉血栓栓塞症的网状Meta 分析
杨婕， 温华， 马冰， 孙晶 - Journal of Pharmaceutical Practice …, 2018 - search.ebscohost.com
… of seven kinds of new oral anticoagulants in prevention of … Following findings ,directly ,Rivaroxaban
and Apixaban were … T AK唱442 an oral factor Xa inhibitor in patients undergo唱 …
and Apixaban were … T AK唱442 an oral factor Xa inhibitor in patients undergo唱 …
直接口服抗凝剂: 一种针对阿尔茨海默病的新疗法?
K Grossmann - 中国神经再生研究(英文版), 2021 - sjzsyj.com.cn
… which include the thrombin inhibitor dabigatran etexilate and blood clotting factor Xa-inhibitors. …
-inhibitors rivaroxaban, apixaban, edoxaban, and betrixaban, are much more suitable. Of …
-inhibitors rivaroxaban, apixaban, edoxaban, and betrixaban, are much more suitable. Of …
[PDF][PDF] 心房颤动抗栓药物治疗进展
马长生 - 临床药物治疗杂志, 2011 - lcywzlzz.com
… Fortunately,the new oral anticOaguIants like dabigatran,ri— varoxaban,apixaban,etc,may
change the current status of antithrombotic therapy in AF patients.This re· … 阿哌沙班(apixaban) …
change the current status of antithrombotic therapy in AF patients.This re· … 阿哌沙班(apixaban) …
新型抗凝药物的研究进展
刘英明， 杨晔 - 临床心血管病杂志, 2012 - lcxxg.whuhzzs.com
… new anticoagulants including direct factor Xa inhibitors,direct thrombin inhibitors and novel
… Rivaroxaban-once daily,oral,direct factor Xa inhibition compared with vita-min K antagonism …
… Rivaroxaban-once daily,oral,direct factor Xa inhibition compared with vita-min K antagonism …
[PDF][PDF] 新型口服抗凝药的特点和临床研究
周建光， 周颖奇 - 2013 - hdhospital.com
… oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor
Xa Inhibitor … Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or …
Xa Inhibitor … Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or …
左心室血栓治疗的系统回顾及meta 分析
周慧贤， 周亚青， 郭甘霖， 崔炜 - 临床荟萃, 2023 - huicui.hebmu.edu.cn
… A total of 25 articles were available for meta analysis to compare the efficacy and adverse
events of novel oral anticoagulants (DOACs) versus vitamin K antagonists (VKA). Currently …
events of novel oral anticoagulants (DOACs) versus vitamin K antagonists (VKA). Currently …
[HTML][HTML] 利伐沙班对预防肺癌相关肺血栓栓塞的研究进展
杨玉婷， 杨华 - Advances in Clinical Medicine, 2021 - hanspub.org
… Rivaroxaban, a new oral anticoagulant, is the earliest direct factor Xa inhibitor on the market
in China, and has greater advantages over traditional low-molecular-weight heparin and …
in China, and has greater advantages over traditional low-molecular-weight heparin and …
[HTML][HTML] 抗凝药物相关骨质疏松症
张翔， 张嘉 - 中华骨质疏松和骨矿盐疾病杂志, 2017 - xml-data.org
… 口服抗凝药目前有2类,除了上述提到的VKAs,另一种即为新型口服抗凝药(new oral anticoagulant
drugs,NOADs).这类药物包括直接凝血酶抑制剂和凝血因子Xa(coagulation factor Xa,FXa)…
drugs,NOADs).这类药物包括直接凝血酶抑制剂和凝血因子Xa(coagulation factor Xa,FXa)…